glp-1 regulations Our first topic in The Pharmacy Gray Zone series covers agonists. This class continues to reshape healthcare and highlight some of the most complex challenges we face across pharmacy practice. From Updated guidance from the PCDS

Introduction Fibrotic diseases, such as metabolic dysfunctionassociated steatotic liver disease (MASLD), chronic kidney disease (CKD), heart failure, neoplasms, and pulmonary disease such as idiopathic pulmonary fibrosis (IPF), are estimated to account for around 35% of global deaths [1]

The involvement of reactive astrocytes in oxidative stress and their contribution to AD has been widely studied

injections of 100 nmol kg 1 GLP-1MK-801 ( n = 8 mice), 10 nmol kg 1 semaglutide ( n = 8 mice) or vehicle (isotonic saline, n = 7 mice) for 5 days with daily measurements of running distance at the time of injection

But success brings a new question that millions of people are confronting: What happens after the weight comes off